CytRx Corporation News
CytRx Corp (CYTR) Posts Q1 Loss of 23c/Share
Street Insider May 9CytRx Reports 2013 First Quarter Financial Results
Business Wire May 9CytRx Corporation , a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three months ended March 3
CytRx Provides Update on Clinical Programs
Benzinga May 8Right Time To Buy This Pharmaceutical Company?
Fool May 7Right Time To Buy This Pharmaceutical Company?
CytRx Receives Recommendation from Data Safety Monitoring Committee to omplete International Phase 2b Trial with Aldoxorubicin
Benzinga May 6CytRx Corp (CYTR) Recommended to Continue Aldoxorubicin Phase 2b to Completion
Street Insider May 6CytRx Receives Recommendation from Data Safety Monitoring Committee to Complete International Phase 2b Trial with Aldoxorubicin as First-Line Treatment for Soft Tissue Sarcoma
Business Wire May 6CytRx Corporation , a biopharmaceutical research and development company specializing in oncology, announced that the independent Data Safety Monitoring Committee overseeing the Company’s international Phase 2b clinical trial with aldoxorubicin as a first-line treatment for patients with late-stage metastatic soft tissue sarcoma has recommended conducting the clinical trial through completion.
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| CYTR | 2.45 | -0.02 | -0.81% | 74.77M |
New watchlist
